Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Jonathan W. Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Christopher A. Yasenchak

Blood (2024) 143 (9): 786–795.

https://doi.org/10.1182/blood.2022019536

Published: 2024

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Shweta Jain, Jingmin Liu, Joseph Thaddeus Beck

Blood (2023) 142 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2023-190260

Published: 2023

Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher A. Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph V. Boccia, Vivian J.M. Cline, Adrija Mamidipalli, Jingmin Liu, Joseph T. Beck

Blood (2022) 140 (Supplement 1): 3685–3686.

https://doi.org/10.1182/blood-2022-156567

Published: 2022

Journal Articles

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Jerome Goldschmidt, MD, Ralph V. Boccia, MD, Vivian J.M. Cline, Mariana Sacchi, MD, Andres Forero-Torres, Robert B. Sims, MD, Jingmin Liu, Jonathan W. Friedberg, MD MSSc

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136583

Published: 2020

Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD

Blood (2019) 134 (Supplement_1): 2852.

https://doi.org/10.1182/blood-2019-122968

Published: 2019

Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 237.

https://doi.org/10.1182/blood-2019-124866

Published: 2019

Journal Articles

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo E. Bordoni, Vivian J. M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang, Christopher A. Yasenchak

Blood (2017) 130 (26): 2829–2837.

https://doi.org/10.1182/blood-2017-06-787200

Published: 2017

Includes: Supplemental data

Journal Articles

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Blood (2016) 128 (22): 104.

https://doi.org/10.1182/blood.V128.22.104.104

Published: 2016

Journal Articles

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Christopher A. Yasenchak, MD, Andres Forero-Torres, Vivian Jean Mikao Cline-Burkhardt, Rodolfo E Bordoni, MD, Dipti Patel-Donnelly, MD, Patrick J. Flynn, MD, Robert Chen, Abraham Fong, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 587.

https://doi.org/10.1182/blood.V126.23.587.587

Published: 2015

Journal Articles

Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Christopher A. Yasenchak, MD, Ahmad Halwani, MD, Ranjana Advani, Stephen Ansell, MD PhD, Lihua Elizabeth Budde, MD PhD, John M. Burke, MD, Charles M. Farber, MD PhD, Beata Holkova, MD, Luis E. Fayad, MD, Kathryn S. Kolibaba, MD, Mark Knapp, MD, Martha Li, PhD, Thomas J. Manley, MD, Dipti Patel-Donnelly, MD, Mahesh Seetharam, MD, Habte A. Yimer, MD, Nancy L Bartlett, MD

Blood (2015) 126 (23): 814.

https://doi.org/10.1182/blood.V126.23.814.814

Published: 2015

Journal Articles

Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study

Christopher A. Yasenchak, MD, Charles M. Farber, MD PhD, Lihua Elizabeth Budde, MD, Stephen M. Ansell, MD PhD, Ranjana Advani, MD, Beata Holkova, MD, Ahmad Halwani, MD, Mark Knapp, MD, Luis Fayad, MD, Kathryn S. Kolibaba, MD, Dipti Patel-Donnelly, MD, Mahesh Seetharam, Thomas J. Manley, MD, Nancy L. Bartlett, MD

Blood (2014) 124 (21): 1745.

https://doi.org/10.1182/blood.V124.21.1745.1745

Published: 2014

Journal Articles

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

James R. Berenson, MD, James D. Hilger, Ph.D., Robert Dichmann, MD, Dipti Patel-Donnelly, MD, Ralph V. Boccia, MD, Alberto Bessudo, MD, Laura V. Stampleman, MD, Donald S. Gravenor, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 4063.

https://doi.org/10.1182/blood.V120.21.4063.4063

Published: 2012

Journal Articles

G-CSF Induced Atypical Monocytic Proliferation Mimicking Acute Myelomonocytic Leukemia in Post-Induction Chemotherapy AML Patient

Rui Rochelle He, MD, Dipti Patel-Donnelly, MD, Arthur N. Kales, MD, Dan Y Qi, MD, Abdus Salam, MD, Hassan Nayer, MD

Blood (2011) 118 (21): 4283.

https://doi.org/10.1182/blood.V118.21.4283.4283

Published: 2011

Journal Articles

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph V. Boccia, MD, Stephen J. Noga, MD, PhD, Donald S. Gravenor, MD, Dipti Patel-Donnelly, MD, Robert S. Siegel, MD, Tarun Kewalramani, MD, Edward J. Gorak, DO, MS, Regina A. Swift, RN, Debra Mayo, PharmD, MHA

Blood (2011) 118 (21): 1857.

https://doi.org/10.1182/blood.V118.21.1857.1857

Published: 2011

Journal Articles

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

Sven de Vos, Shaker Dakhil, Peter McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Mark Knapp, Lowell Hart, Dipti Patel-Donnelly, Martha Glenn, Stephanie A. Gregory, Charles Holladay, Anthony Boral, Tracy Zhang, André Goy

Blood (2005) 106 (11): 17.

https://doi.org/10.1182/blood.V106.11.17.17

Published: 2005

NARROW

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

G-CSF Induced Atypical Monocytic Proliferation Mimicking Acute Myelomonocytic Leukemia in Post-Induction Chemotherapy AML Patient

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only